Skip to content

First Tracks Biotherapeutics

US · TRAX #3189 by market cap Listed 2026
41.64 -2.82 -6.34%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 43.51 -2.14%
After-hours 40.70 -2.26%
52.3315.3241.642026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on TRAX?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -0.6% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has risen to 14.1% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days C → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-21 20:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall A-

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Return on equity -40.9% Better than 10%
Return on invested capital -43.4% Better than 7%
Momentum A-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -3.4% Better than 66%
6-month return 142.4% Better than 100%
Distance below 52-week high 24.0% Better than 52%
Financial Health A+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 10.8x Better than 94%
Debt to assets 3.6% Better than 83%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 81.1% Better than 79%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -11.59%
1M +0.95%
3M -0.62%
6M +157.51%

Key statistics

Price & volume

Prev close
44.46
Open
43.99
Day range
41.23 - 44.74
Avg price
42.18
Volume
504.37K
Turnover
21.27M
Amplitude
7.90%
52-week range
14.72 - 54.78

Valuation

P/E
-8.46
P/E (TTM)
-9.98
P/B
11.59
EPS
-4.92
Net profit
-206.85M
Net assets
151.01M

Share structure

Market cap
1.75B
Float cap
1.10B
Shares out
42.02M
Float shares
26.33M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2026-04-06
52-week range 67% of range
14.72 54.78

24.0% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+1.35M net over the window

Short interest

Shares short
5.06M
As of
2026-10-30

Frequently asked questions

What is the current stock price of First Tracks Biotherapeutics (TRAX)?

First Tracks Biotherapeutics last traded at 41.64. This page shows a periodic quote snapshot. Check the displayed quote time.

What is First Tracks Biotherapeutics's market cap?

About 1.75B.

What is the P/E ratio of First Tracks Biotherapeutics?

The trailing twelve-month P/E is -9.98. The Valuation tab shows it against the stock's own five-year range.

Does First Tracks Biotherapeutics pay a dividend?

First Tracks Biotherapeutics does not currently pay a regular dividend.

Is First Tracks Biotherapeutics a buy according to analysts?

The consensus of 10 analysts is a Buy rating, with an average 12-month price target of 75.40, which implies 81.1% upside from the current price. This is not investment advice.

What is First Tracks Biotherapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates First Tracks Biotherapeutics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

First Tracks Biotherapeutics discussion 0 comments

Add a comment